Buschke–Ollendorff syndrome
| Buschke–Ollendorff sign | |
|---|---|
| Synonyms | Dermatofibrosis lenticularis disseminata<ref name="Bolognia">{{{last}}},
Rapini, Ronald P., Dermatology: 2-Volume Set, St. Louis:Mosby, 2007, ISBN 978-1-4160-2999-1,</ref> |
| Pronounce | |
| Field | |
| Symptoms | Osteopoikilosis, bone pain<ref name=gar/> |
| Complications | |
| Onset | |
| Duration | |
| Types | |
| Causes | Mutations in the LEMD3 gene.<ref name=gar/> |
| Risks | |
| Diagnosis | X-ray, ultrasound<ref name=orph/> |
| Differential diagnosis | |
| Prevention | |
| Treatment | Surgery for hearing loss(or complications)<ref name=emed/> |
| Medication | |
| Prognosis | |
| Frequency | |
| Deaths | |
Buschke–Ollendorff syndrome is a rare genetic disorder associated with LEMD3. It is believed to be inherited in an autosomal dominant manner.<ref name=omim>Online Mendelian Inheritance in Man (OMIM) 166700
</ref> It is named for Abraham Buschke and Helene Ollendorff Curth,<ref>A. Buschke, H. Ollendorff-Curth. Ein Fall von Dermatofibrosis lenticularis disseminata und Osteopathia condensans disseminata. Dermatologische Wochenschrift, Hamburg, 1928, 86: 257–262.</ref> who described it in a 45-year-old woman. Its frequency is almost 1 case per every 20,000 people, and it is equally found in both males and females.<ref name="emed">
</ref>
Signs and symptoms[edit]

The signs and symptoms of this condition are consistent with the following (possible complications include aortic stenosis and hearing loss<ref name="gar">
Buschke Ollendorff syndrome | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program(link). rarediseases.info.nih.gov.
</ref><ref name=emed/>):
- Osteopoikilosis
- Bone pain
- Connective tissue nevi
- Metaphysis abnormality
Pathogenesis[edit]
Buschke–Ollendorff syndrome is caused by one important factor: mutations in the LEMD3 gene (12q14), located on chromosome 12. (May 2018)
Among the important aspects of Buschke–Ollendorff syndrome condition, genetically speaking are:<ref>
Reference, Genetics Home.
Buschke-Ollendorff syndrome(link).
Genetics Home Reference.
Accessed 2018-05-13.
</ref><ref>,
Laminopathies and the long strange trip from basic cell biology to therapy, The Journal of Clinical Investigation, Vol. 119(Issue: 7), pp. 1825–1836, DOI: 10.1172/JCI37679, PMID: 19587457, PMC: 2701866, Full text,</ref><ref>
Reference, Genetics Home. LEMD3 gene(link). Genetics Home Reference.
Accessed 2018-05-13.
</ref>

- LEMD3 (protein) referred also as MAN1, is an important protein in inner nuclear membrane.
- LEMD3 gene gives instructions for producing protein that controls signaling for transforming growth factor-beta.
- LEMD3 gene helps in the bone morphogenic protein pathway
- Both of the above pathways help grow new bone cells
- BMP and TGF-β pathways controls SMADs proteins, which then bind to DNA
- LEMD3 once mutated, causes a reduction of the protein, which in turn causes excess of the above two pathways.
Diagnosis[edit]


-Creative Commons Attribution 3.0 Unported license</ref>
The diagnosis of this condition can be ascertained via several techniques one such method is genetic testing, as well as:<ref name=gar/><ref name=orph/>
- X-ray
- Ultrasound
- Histological test
Differential diagnosis[edit]
The differential diagnosis for an individual believed to have Buschke–Ollendorff syndrome is the following:<ref name="orph">
Orphanet: Buschke Ollendorff syndrome(link). www.orpha.net.
</ref>
- Melorheostosis
- Sclerotic bone metastases.
Treatment[edit]
In terms of the treatment of Buschke–Ollendorff syndrome, should the complication of aortic stenosis occur then surgery may be required. Treatment for hearing loss may also require surgical intervention.<ref name=emed/>
See also[edit]
References[edit]
Further reading[edit]
- ,
Buschke-Ollendorff syndrome: a novel case series and systematic review, The British Journal of Dermatology, 2016, Vol. 174(Issue: 4), pp. 723–729, DOI: 10.1111/bjd.14366, PMID: 26708699,
- ,
Radiological findings in skin diseases and related conditions. online version, Stuttgart:Thieme, ISBN 9783131161215,
External links[edit]
| Medicine | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
